

COVID-19 Vaccine Update

Health Disparity Task Force

Objectives

- Review TN COVID-19 vaccine uptake metrics
- Highlight COVID-19 vaccine dates of interest
- Discuss vaccine booster dose planning
- Discuss Pediatric COVID-19 vaccine formulation timelines



Vaccine Update (as of 10/25/21)

- 7,202,587 doses administered
- Tennesseans with at least one dose (% of total population)
 - -3,680,580 or 53.9% (up from 53.6%) ¹
 - -National rate = 66.4% (up from 65.9%)²
- Tennesseans fully immunized (% of total population)
 - -3,298,009 or 48.3% (up from 47.9%) ¹
 - National rate = 57.4% (up from 57.0%)²


¹ As reported by TennIIS: https://www.tn.gov/health/cedep/ncov/covid-19-vaccine.html

² As reported by CDC: https://covid.cdc.gov/covid-data-tracker/#vaccinations

Vaccine Uptake Trends


Total Number of COVID-19 Vaccine Doses Administered and Reported to TennIIS

By Week of Adminstration and Vaccine Manufacturer



Tennessee Ranking³

- 40th for vaccine administration/100K population
- 42nd for % of total population with at least one dose
- 43rd for % of total population fully vaccinated



Percent of Population Receiving at Least One Dose

○ No Data ○ 0% ○ 0.1 - 49.9% ○ 50 - 59.9% ○ 60 - 69.9% ○ 70 - 84.9% ○ ≥85%

Vaccine Uptake, Top and Bottom 10 (at least one dose)

Highest (%)		L	Lowest (%)	
MEIGS	68.3	TROUSDALE	36.0	
MADISON	64.0	SEQUATCHIE	35.6	
LOUDON	63.9	OVERTON	35.3	
WILLIAMSON	63.1	HANCOCK	33.7	
MAURY	62.5	FENTRESS	33.5	
DAVIDSON	62.2	SMITH	32.8	
WASHINGTON	59.9	GRUNDY	31.6	
KNOX	58.4	MACON	31.3	
VAN BUREN	58.2	CANNON	31.1	
FAYETTE	56.1	MOORE	22.5	

¹As reported by TennIIS: https://www.tn.gov/content/tn/health/cedep/ncov/COVID-19-Vaccine.html

Who is Eligible for a Booster Dose of Pfizer and Moderna COVID-19 vaccine?

- Recipients of an mRNA primary series are eligible to receive a single mRNA COVID-19 vaccine booster dose ≥ 6 months after completion of primary series
 - 65 years and older
 - Age 18+ who live in <u>long-term care settings</u>
 - Age 18+ who have underlying medical conditions
 - Age 18+ who work or live in <u>high-risk settings</u>
- In general, the same product that was used for the primary regimen should be used for the booster.
- NEW APPROVAL: Heterologous (or "mix and match") booster dose in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine.

Who is Eligible for a Booster Dose of Janssen (JnJ) COVID-19 vaccine?

- Recipients of a single dose Janssen primary series are eligible to receive a single Janssen COVID-19 vaccine booster dose ≥ 2 months after completion of primary series
 - Age 18+
- In general, the same product that was used for the primary regimen should be used for the booster.
- NEW APPROVAL: Heterologous (or "mix and match") booster dose in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine.

Who is Eligible for a Booster Dose of COVID-19 vaccine Current SUMMARY

Vaccine	Primary Series	Additional Dose for Immunocomp	Booster Dose
Pfizer- BioNTech	≥12 years	≥12 years	≥ 18 years*
Moderna	≥ 18 years	≥ 18 years	≥ 18 years*#
Janssen	≥ 18 years	See booster dose	≥ 18 years

* Refer to Eligible population Slide

- -65 years and older
- -Age 18+ who live in long-term care settings
- -Age 18+ who have underlying medical conditions
- -Age 18+ who work or live in high-risk settings

Moderna booster is a half dose

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html

Co-administration with other vaccines

 COVID-19 vaccine booster dose (Pfizer-BioNTech, Moderna, or Janssen) may be given with other vaccines, without regard to timing.

 This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day.

 If multiple vaccines are administered at a single visit, administer each injection in a different injection site.

Pfizer Pediatric COVID-19 vaccine formulation

- FDA Advisory Group Meeting October 26
 - –Pfizer formulation for children aged 5-11
 - Emergency Use Authorization

• Next ACIP (CDC Advisory Group) meetings:

(https://www.cdc.gov/vaccines/acip/index.html)

- -November 2-3
- Vaccine Pre-ordering happening now!

Pfizer Pediatric COVID-19 vaccine formulation

Pfizer-BioNTech COVID-19 Vaccines

PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL

Description	Current Adult/Adolescent Formulation (1170 and 450 packs)	Future Pediatric Formulation			
	Dilute Prior to Use	Dilute Prior to Use			
Age Group	12 years and older	5 to <12 years**			
Vial Cap Color	PURPLE	ORANGE			
Dose	30 mcg	10 mcg			
Injection Volume	0.3 mL	0.2 mL			
Fill Volume (before dilution)	0.45 mL	1.3 mL			
Amount of Diluent* Needed per Vial	1.8 mL	1.3 mL			
Doses per Vial	6 doses per vial (after dilution)	10 doses per vial (after dilution)			
Storage Conditions					
ULT Freezer (-90°C to -60°C)	9 months	6 months			
Freezer (-25°C to -15°C)	2 weeks	N/A			
Refrigerator (2°C to 8°C)	1 month	10 weeks			

Q: Can the current adult/adolescent formulation (purple cap) be used to vaccinate children 5 to <12 years old once the vaccine is authorized for this age group?

A: No. For children under 12 years of age, you cannot use the current formulation and will need to use the future pediatric (orange cap) formulation.

Purple Cap – Adult/Adolescent: Authorized only for aged 12 years and older



Orange Cap – Pediatric: Future authorization for aged 5to 12 years. A separate vaccine formulation specific for a 10mcg dose will be introduced.



<u>NOTE</u>: Use of the current adult/adolescent formulation (purple cap) to prepare doses for children 5 to <12 years would result in an injection volume for the 10mcg dose of 0.1mL, which is both generally considered too small for typical IM injections and has not been studied.

^{*}Diluent: 0.9% sterile Sodium Chloride Injection, USP (non-bacteriostatic; DO NOT USE OTHER DILUENTS

^{**}The vaccine is currently under emergency use authorization review by the Food and Drug Administration (FDA) for children 5 to <12 years old

Moderna Pediatric COVID-19 vaccine formulation

No dose for less than 18 years of age available yet

- Moderna has submitted scientific data to FDA
 - -12 to 18 years old
 - -6 to 11 years old
- Authorization timelines for these age groups are unknown currently

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-teencove-study-its-covid-19-vaccine

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-top-line-data-phase-23-study-covid-19

Where do I go to Find a COVID-19 vaccine?

www.Vaccines.gov

Find a COVID-19 vaccine near you

Use Vaccines.gov to find a location near you, then call or visit their website to make an appointment.

Find COVID-19 Vaccines

I'm looking for flu vaccines -

Powered by VaccineFinder





FIGHT FLU TN 2021

100+ Flu Clinics are planned for during #FightFluTN

- -Nov. 9, 2021
- Focus will be on vulnerable populations and improving community engagement
- Resources being developed in braille and sign language videos
- Comprehensive media campaign resources being developed
- More info can be found at: https://www.tn.gov/health/fightflu







THANK YOU! Questions? VPDIP.pandemic@tn.gov